Imperative Care Closes $100M Convertible Note Financing

Why It Matters

The infusion of $100 million gives Imperative Care the resources to scale its clot‑removal technologies and bring robotic precision to vascular interventions, potentially reshaping the stroke‑treatment market. It also signals strong investor confidence in AI‑driven medical devices, underscoring growth opportunities in the cardiovascular sector.

Key Takeaways

• Imperative Care raised $100M via convertible notes
• Round led by Elevage Medical and Perceptive Advisors
• Existing backers include Catalio, Ally Bridge, Bain Capital
• Company markets Zoom Stroke, Symphony, Prodigy thrombectomy systems
• Developing Telos robotic platform for precise endovascular procedures

Pulse Analysis

Thromboembolic disease, encompassing ischemic stroke and other clot‑related conditions, remains a leading cause of mortality worldwide, driving demand for rapid, effective interventions. Imperative Care has positioned itself at the forefront of this market with three FDA‑cleared thrombectomy systems—Zoom Stroke, Symphony, and Prodigy—that enable clinicians to remove clots quickly and restore blood flow. By combining proprietary catheter technology with advanced imaging integration, the company addresses a critical gap in acute care, offering hospitals a scalable solution that can improve patient outcomes and reduce procedural times.

The $100 million convertible note round, led by Elevage Medical Technologies and Perceptive Advisors, underscores strong capital appetite for vascular‑tech innovators. Convertible notes give investors upside participation while providing Imperative Care with non‑dilutive financing that can be converted into equity as the company meets milestones. Existing backers such as Catalio Capital, Ally Bridge Group and Bain Capital Life Sciences reaffirm confidence in the firm’s commercial traction, while newcomers Longaeva Partners and Brown Advisory broaden the strategic network. The proceeds are earmarked for scaling sales of the thrombectomy portfolio and accelerating the Telos robotic platform’s development.

Looking ahead, Imperative Care’s Telos robotic system could redefine endovascular procedures by delivering sub‑millimeter precision and standardizing technique across operators. Robotic assistance promises reduced radiation exposure for physicians and consistent outcomes for patients, aligning with broader industry trends toward automation and remote care. If the platform reaches regulatory clearance, it may open new revenue streams and expand the company’s addressable market beyond stroke to peripheral artery disease and deep‑vein thrombosis. Competitors are racing to commercialize similar technologies, making the infusion of capital a decisive factor in securing first‑mover advantage.

Deal Summary

Imperative Care, a medical technology firm focused on thromboembolic disease treatments, has closed a $100 million convertible note financing. The round was co‑led by Elevage Medical Technologies and Perceptive Advisors, with participation from Catalio Capital Management, Longaeva Partners, Brown Advisory, Ally Bridge Group and Bain Capital Life Sciences.